An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A

Summary

The safety and efficacy of sucrose-formulated recombinant factor VIII (rFVIII-FS; Kogenate^® FS) under usual clinical practice were evaluated for 12 months in an observational, postmarketing surveillance study conducted at 214 treatment centres throughout Japan. The study included 631 patients with haemophilia A, 80% of whom had severe or moderately-severe disease (≤2% FVIII:C).Most patients (n=477;75.6%) had >100 prior exposure days (EDs), but the study also included 62 (9.8%) patients with <20 EDs who were at high risk for inhibitor development. A total of 71,240 infusions were administered during the observation (mean, 113 ± 108 per patient). Physicians rated efficacy and tolerability of rFVIII-FS as “very good” or “good” in >99% of patients. FVIII inhibitors were observed in seven patients (5 de novo; 1 persistent/fluctuating; 1 recurrent).The overall de novo inhibitor incidence was 0.8% (5/631; or 5/599 among the subgroup of patients with negative baseline titre and no known inhibitor history).De novo cases represented 3.2% (2/62) of patients with <20 EDs at enrollment (2/57 in the no inhibitor subgroup) and 0.2 % (1/477) of patients pretreated with >100 EDs (1/452 in the no inhibitor subgroup) at enrollment. The results of this large observational study demonstrate that rFVIII-FS is both safe and efficacious as used in the usual clinical setting for the treatment of Japanese patients with mild to severe haemophiliaA. This study supports the efficacy of rFVIII-FS with an incidence of inhibitor formation no greater than in a comparable European study or previous phase III clinical studies.

Keywords

Haemophilia A - Kogenate - recombinant factorVIII - inhibitors

• References

• 1 Pool JG, Gershgold EJ, Pappenhagen AR. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature 1964; 203: 312.
• 2 Tuddenham EG. In search of the eighth factor: a personal reminiscence. J Thromb Haemost 2003; 01: 403-409.
• 3 Abshire TC, Brackmann HH, Scharrer I. et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy. Thromb Haemost 2000; 83: 811-816.
• 4 Lee DC, Miller JL, Petteway Jr SR. Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE Bayer. Haemophilia 2002; 08 (Suppl. 00) 6-9.
• 5 Kreuz W, Gill JC, Rothschild C. et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost 2005; 93: 457-467.
• 6 Oldenburg J, Ivaskevicius V, Schroder J. et al. Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII. Thromb Haemost 2006; 95: 903-905.
• 7 Luboshitz J, Lubetsky A, Maas-Enriquez M. et al. Clinical evaluation of continuously infused sucrose-formulated recombinant factor VIII during surgery. Haemophilia 2006; 12 (Suppl. 00) 05PO102.
• 8 Scharrer I, Brackmann HH, Sultan Y. et al. Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A. Haemophilia 2000; 06: 614-618.
• 9 Lusher JM. First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Semin Thromb Hemost 2002; 28: 273-276.
• 10 Peerlinck K, Hermans C. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia 2006; 12: 579-590.
• 11 White GC, DiMichele D, Mertens K. et al. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1999; 81: 462.
• 12 Kreuz W, Ettingshausen CE, Zyschka A. et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost 2002; 28: 285-290.
• 13 Oldenburg J, Schroder J, Brackmann HH. et al. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004; 41: 82-88.
• 14 Hay CR, Ollier W, Pepper L. et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. Thromb Haemost 1997; 77: 234-237.
• 15 Oldenburg J, Picard JK, Schwaab R. et al. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 238-242.
• 16 Astermark J, Oldenburg J, Carlson J. et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-3745.
• 17 Antihemophilic Factor (Recombinant) Kogenate FS Formulated with Sucrose [prescribing information]. Bayer HealthCare; Ta rrytown, NY: 2007
• 18 Musso R, Santagostino E, Faradji A. et al. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting. Thromb Haemost 2008; 99: 52-58.
• 19 Pollmann H, Externest D, Ganser A. et al. Efficacy, safety and tolerability of recombinant factor VIII (RE-FA CTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia 2007; 13: 131-143.
• 20 Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-4654.
• 21 Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haematologica 2000; 85: 7-14.
• 22 Neugebauer B, Drai C, Haase M. et al. Factor VIII products and inhibitor development: concepts for revision of European regulatory guidelines. Haemophilia 2008; 14: 142-144.
• 23 Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 04: 2576-2581.
• 24 Cho YK, Foley BT, Sung H. et al. Molecular epidemiologic study of a human immunodeficiency virus 1 outbreak in haemophiliacs B infected through clotting factor 9 after 1990. Vox Sang 2007; 92: 113-120.
• 25 Jee YM, Go U, Cheon D. et al. Detection of hepatitis A virus from clotting factors implicated as a source of HAV infection among haemophilia patients in Korea. Epidemiol Infect 2006; 134: 87-93.
• 26 Kernoff PB, Lee CA, Karayiannis P. et al. High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol 1985; 60: 469-479.
• 27 Lee CA, Phillips A, Elford J. et al. The natural history of human immunodeficiency virus infection in a haemophilic cohort. Br J Haematol 1989; 73: 228-234.
• 28 Yee TT, Lee CA. Transfusion-transmitted infection in hemophilia in developing countries. Semin Thromb Hemost 2005; 31: 527-537.